These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 20479444

  • 1. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A, Agnew P, Parish L, Joseph R, Galiano RD.
    J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 3. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D.
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Mar; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 5. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [Abstract] [Full Text] [Related]

  • 6. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
    Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.
    Inflammation; 2002 Feb; 26(1):19-24. PubMed ID: 11936752
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Feb; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 10. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers.
    Veves A, Sheehan P, Pham HT.
    Arch Surg; 2002 Jul; 137(7):822-7. PubMed ID: 12093340
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Jun; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 13. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H, Supe A.
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [Abstract] [Full Text] [Related]

  • 14. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Jun; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR, Gilligan AM, Motley TA.
    J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
    [Abstract] [Full Text] [Related]

  • 16. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

  • 17. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Feb; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Nov; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 20. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.